2, 3 Rivaroxaban and an additional Xa inhibitor, betrixaban, are Food and Drug Administration–approved for extended venous thromboembolic prophylaxis in medically ill, hospitalized patients. 1–3 Rivaroxaban and apixaban are approved for extended venous thromboembolic prophylaxis. 1–4 Dabigatran, apixaban, and rivaroxaban are approved for venous thromboembolic prophylaxis after hip and knee replacement surgery. Food and Drug Administration and European Medicines Agency for treatment of venous thromboembolism and prevention of stroke in nonvalvular atrial fibrillation. The direct thrombin inhibitor dabigatran and the Xa inhibitors apixaban, rivaroxaban, and edoxaban have been approved by the U.S. Large phase III randomized controlled trials comparing direct oral anticoagulants to either vitamin K antagonists or low-molecular-weight heparin have demonstrated similar or better safety and efficacy for many indications. The direct oral anticoagulants are approved and prescribed for a number of indications to prevent and treat thromboembolic disease.
0 kommentar(er)
